Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
TNDM · Nasdaq · United States · Surgical & Medical Instruments & Apparatus
In shortTANDEM DIABETES CARE INC is loss-making, burns cash and carries moderate debt, with revenue growing (+7.9% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -18.5% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -20.2% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -97.9% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -31.8% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.55× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 2.00× | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -23.68× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -3.04 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -2.9% | 8/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 18.0% | 44/100 |
| Operating margin volatility | 12.5% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 8.2% | 62/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 703 | 801 | 748 | 940 | 1,015 |
| Cost of revenue | 327 | 388 | 380 | 451 | 469 |
| Gross profit | 376 | 413 | 368 | 490 | 546 |
| Research & development | 92 | 139 | 170 | 199 | 193 |
| Selling, general & admin | 262 | 336 | 353 | 390 | 445 |
| Operating income | 23 | (93) | (233) | (99) | (187) |
| Interest expense | – | 6.2 | 9.9 | 7.4 | 7.9 |
| Pre-tax income | 16 | (93) | (220) | (92) | (200) |
| Income tax | 0.3 | 1.7 | 2.4 | 4.2 | 4.4 |
| Net income | 16 | (95) | (223) | (96) | (205) |
| Diluted EPS | $0.24 | −$1.47 | −$3.43 | −$1.47 | −$3.04 |
| Diluted shares (millions) | 64 | 64 | 65 | 65 | 67 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of TANDEM DIABETES CARE INC are included in the Investor plan. Try free for 7 days →
−3.04 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026